that’s great to just focus on the best part of the business. They should have just pumped 10 billion into the Behring side of the company. The only slim upside I see to vifor is blood collection integration through Behring, however it seems an expensive way to collect blood compared to what is proven. Just the interest expense has grown 32 percent this year. I’m all out for now, will look at it again later on.
Ann: Statutory Accounts for the Half Year Ended 31 December 2023, page-25
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$306.03 |
Change
0.290(0.09%) |
Mkt cap ! $147.8B | |||
| Open | High | Low | Value | Volume |
| $304.40 | $307.10 | $303.30 | $145.5M | 477.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 157 | $306.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $306.54 | 305 | 1 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| CSL (ASX) Chart |